MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Eli Lilly and Co.

Geschlossen

BrancheGesundheitswesen

844.9 0.11

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

842.5

Max

854.77

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.9B

5.7B

Verkäufe

2.8B

16B

KGV

Branchendurchschnitt

47.515

35.739

EPS

6.31

Dividendenrendite

0.77

Gewinnspanne

36.384

Angestellte

47,000

EBITDA

3.3B

7.5B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+7.91% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.77%

3.08%

Nächstes Ergebnis

30. Okt. 2025

Nächste Dividendenausschüttung

9. Dez. 2025

Nächstes Ex-Dividendendatum

14. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-39B

651B

Vorheriger Eröffnungskurs

844.79

Vorheriger Schlusskurs

844.9

Nachrichtenstimmung

By Acuity

34%

66%

122 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Eli Lilly and Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Sept. 2025, 03:10 UTC

Akquisitionen, Fusionen, Übernahmen

South Korea's Celltrion Plans to Invest $1 Billion to Acquire, Expand U.S. Facility

25. Aug. 2025, 15:59 UTC

Wichtige Markttreiber

Immuneering Shares Climb On Supply Agreement with Eli Lilly

7. Aug. 2025, 11:36 UTC

Ergebnisse

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand

26. Sept. 2025, 13:55 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Eli Lilly, Intel, Paccar, GlobalFoundries, Boeing, Concentrix, Costco, and More -- Barrons.com

26. Sept. 2025, 09:41 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Eli Lilly, Wayfair, Intel, Oracle, Concentrix, Costco, and More -- Barrons.com

23. Sept. 2025, 02:55 UTC

Akquisitionen, Fusionen, Übernahmen

South Korea's Celltrion Plans to Invest $1B to Acquire, Expand U.S. Facility

23. Sept. 2025, 01:27 UTC

Akquisitionen, Fusionen, Übernahmen

Celltrion: Investment Aims to Remove U.S. Tariff Risks

23. Sept. 2025, 01:26 UTC

Akquisitionen, Fusionen, Übernahmen

Celltrion: To Invest Extra KRW700B to Expand Facility in Branchburg, New Jersey

23. Sept. 2025, 01:26 UTC

Akquisitionen, Fusionen, Übernahmen

Celltrion: To Spend KRW700B for Acquisition, Initial Operating Costs

23. Sept. 2025, 01:25 UTC

Akquisitionen, Fusionen, Übernahmen

Celltrion to Buy Biologics Facility in U.S. for $330M From Eli Lilly

22. Sept. 2025, 13:43 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

26. Aug. 2025, 13:57 UTC

Ergebnisse

These Stocks Are Moving the Most Today: EchoStar, AT&T, AMD, Lilly, DJT, Talen Energy, Semtech, and More -- Barrons.com

26. Aug. 2025, 11:37 UTC

Ergebnisse

These Stocks Are Moving the Most Today: AT&T, EchoStar, AMD, Lilly, Interactive Brokers, Talen Energy, and More -- Barrons.com

12. Aug. 2025, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

8. Aug. 2025, 19:34 UTC

Market Talk

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8. Aug. 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7. Aug. 2025, 16:20 UTC

Ergebnisse

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

7. Aug. 2025, 14:18 UTC

Market Talk
Ergebnisse

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

7. Aug. 2025, 13:54 UTC

Ergebnisse

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

7. Aug. 2025, 12:12 UTC

Ergebnisse

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

7. Aug. 2025, 11:58 UTC

Ergebnisse

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

7. Aug. 2025, 11:32 UTC

Ergebnisse

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. Aug. 2025, 11:03 UTC

Ergebnisse

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. Aug. 2025, 10:49 UTC

Ergebnisse

Eli Lilly 2Q Gross Margin 84.3% >LLY

7. Aug. 2025, 10:48 UTC

Ergebnisse

Eli Lilly 2Q Volume Rose 42%, Realized Prices Fell 6% >LLY

7. Aug. 2025, 10:47 UTC

Ergebnisse

Eli Lilly Raises 2025 Adjusted Performance Margin View to 43%-44.5% From 41.5%-43.5% >LLY

7. Aug. 2025, 10:46 UTC

Ergebnisse

Eli Lilly Had Seen 2025 Adjusted EPS $20.78-$22.28 >LLY

7. Aug. 2025, 10:46 UTC

Ergebnisse

Eli Lilly Had Seen 2025 Revenue $58B-$61B >LLY

7. Aug. 2025, 10:46 UTC

Ergebnisse

Eli Lilly Raises 2025 View To Rev $60B-$62B >LLY

7. Aug. 2025, 10:45 UTC

Ergebnisse

Eli Lilly 2Q Net $5.66B >LLY

Peer-Vergleich

Kursveränderung

Eli Lilly and Co. Prognose

Kursziel

By TipRanks

7.91% Vorteil

12-Monats-Prognose

Durchschnitt 910.39 USD  7.91%

Hoch 1,190 USD

Tief 700 USD

Basierend auf 22 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Eli Lilly and Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

22 ratings

18

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

N/A / 884.54Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

122 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
help-icon Live chat